Discuss TB-500 + BPC-157 on glp1chat
Join the forum to discuss research with other members.
At a glance
This record describes separate TB-500 and BPC-157 vials. BPC-157 has been studied for collagen and blood-vessel changes in injured tissue; thymosin-related research examines how cells move during repair. Findings for either component do not establish the effect of using both together.
These are separate vials, so the record is not one new molecule. BPC-157 has been examined in animal injury models, while thymosin-related work looks at cell movement and tissue organization. The purpose of pairing them is to explore different parts of the repair process. Whether both together change an outcome is a separate experiment, and the exact TB-500 sequence must be known.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of TB-500 + BPC-157.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg + 5 mg · 2 source tables
TB-500 Protocol (2 mL Reconstitution = 2.5 mg/mL)
| Week | Dose (mcg) | Units (per injection) (mL) | Frequency |
|---|---|---|---|
| Weeks 1–4 | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) | Twice weekly |
| Weeks 5–12 | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) | Once weekly |
Route: Subcutaneous injection. The loading phase (Weeks 1–4) uses twice-weekly dosing to establish tissue saturation, followed by a maintenance phase (Weeks 5–12) at once weekly[1].
BPC-157 Protocol (2 mL Reconstitution = 2.5 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) | Frequency |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 10 units (0.10 mL) | Once daily |
| Weeks 3–8 | 500 mcg (0.50 mg) | 20 units (0.20 mL) | Once daily |
| Weeks 9–12 | 250 mcg (0.25 mg) | 10 units (0.10 mL) | Once daily |
Route: Subcutaneous injection, preferably near the site of injury. Preclinical research commonly uses 250–500 mcg per day for musculoskeletal applications[3][4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the combined regimen.
- Goal: Support tissue repair, reduce inflammation, and accelerate recovery from musculoskeletal injuries[1][3].
- Schedule: TB-500 twice weekly (loading) then once weekly (maintenance); BPC-157 daily throughout.
- Dose Range: TB-500: 1,250 mcg per injection; BPC-157: 250–500 mcg daily.
- Reconstitution: 2.0 mL per 5 mg vial for both peptides (~2.5 mg/mL).
- Storage: Refrigerate lyophilized and reconstituted solutions; use within ~30 days after reconstitution.
Suggested combined approach for synergistic tissue support.
- TB-500 Loading: 1,250 mcg twice weekly for 4 weeks (total ~2.5 mg/week).
- TB-500 Maintenance: 1,250 mcg once weekly for Weeks 5–12.
- BPC-157 Start: 250 mcg daily for 2 weeks, then increase to 500 mcg daily.
- BPC-157 Taper: Return to 250 mcg daily for final 4 weeks (Weeks 9–12).
- Timing: Inject at consistent times; BPC-157 preferably near injury site.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
TB-500 Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
BPC-157 Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F); for long-term storage, −20 °C (−4 °F) is acceptable[9].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~30 days; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7][8].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[8].
- For BPC-157, injecting near the injury site may enhance local effects[4].
Materials & quantity planning
Source materials checklist · 5 mg + 5 mg
Plan based on an 8–16 week combined protocol with the schedules above.
-
TB-500 Vials (5 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
-
BPC-157 Vials (5 mg each):
- 8 weeks ≈ 5 vials
- 12 weeks ≈ 7 vials
- 16 weeks ≈ 8 vials
-
Insulin Syringes (U-100):
- 8 weeks: 68 syringes (TB-500: 12 + BPC-157: 56)
- 12 weeks: 100 syringes (TB-500: 16 + BPC-157: 84)
- 16 weeks: 132 syringes (TB-500: 20 + BPC-157: 112)
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (8 total vials): 16 mL → 2 × 10 mL bottles
- 12 weeks (11 total vials): 22 mL → 3 × 10 mL bottles
- 16 weeks (13 total vials): 26 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- 8 weeks: ~160 swabs → recommend 2 × 100-count boxes
- 12 weeks: ~232 swabs → recommend 3 × 100-count boxes
- 16 weeks: ~304 swabs → recommend 4 × 100-count boxes
View Supplier
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
Frontiers in Endocrinology (2021) — Progress on the Function and Application of Thymosin β4 (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
Annals of the New York Academy of Sciences — Thymosin β4: roles in development, repair, and engineering of the cardiovascular system (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
Frontiers in Pharmacology (2022) — Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
HSS Journal (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
Current Pharmaceutical Design (2018) — Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
Journal of Orthopaedic Surgery and Research (2019) — BPC 157 and its effects on tendon healing (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
CDC (2024) — Vaccine Administration: Subcutaneous (SUBCUT) Injection (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf (2023) — Administration of Parenteral Medications – Nursing Skills (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.